3DMed Overseas

3D Medicines (3DMed), founded in 2010, is a leader in precision medicine in China dedicated to making early and personalized diagnosis accessible to each patient.

3DMed clinical laboratory is accredited by College of American Pathologists (CAP) and certified by Clinical Laboratory Improvement Amendments (CLIA) to provide clinical testing in various disease areas. 

In 2018, 3DMed introduced an AI-based cancer genome data interpretation system, the ANDiS Genome Insight. In 2019, 3DMed launched the world’s first fully closed automated NGS library-prep system, the ANDiS 400. 

Soon after the coronavirus 2019 (COVID-2019) outbreak, 3DMed responded rapidly by developing a series of RT-qPCR-based tests (the ANDiS SARS-CoV-2 Detection Kit and the ANDiS SARS-CoV-2 & Influenza A/B Detection Kit) for qualitative detection of SARS-CoV-2 RNA in upper and lower respiratory specimens collected from individuals who meet the CDC criteria for SARS-CoV-2 testing.